BBH241220C168000
- 13.50
- 0.000.00%
VanEck Biotech ETF Newsroom
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Novo Nordisk, Super Micro Computer And Arm Are Among Top Large Cap Losers Last Week (December 16-20): Are The Others In Your Portfolio?
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Press Release: VanEck Announces Year-End Distributions for VanEck Equity ETFs
VanEck Biotech ETF To Go Ex-Dividend On December 23rd, 2024 With 1.2517 USD Dividend Per Share
December 20th (Eastern Time) - $VanEck Biotech ETF(BBH.US)$ is trading ex-dividend on December 23rd, 2024.Shareholders of record on December 23rd, 2024 will receive 1.2517 USD dividend per share on
Traders Fight The Grinch To Save The Santa Rally: 10 S&P 500 Stocks Poised For A Year-End Surge
Vertex Announces U.S. FDA Approval For TRIKAFTA To Include Additional Non-F508del TRIKAFTA-Responsive Variants
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
What's Going On With Amgen Stock On Friday?
BMO Capital Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $520
J.P. Morgan's Top Healthcare Stocks for 2025
Why Is Novo Nordisk Crashing After Data for Next-gen Weight Loss Drug?
This Nike Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday
Amgen Shares Are Trading Higher. Weight-loss Related Stocks Are up on Friday Following Weaker-than-expected Data From Competitor Lilly.
Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold
The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.
The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.
BMO Capital Downgrades Biogen to Market Perform, Lowers Price Target to $164
Biogen Analyst Ratings
The Dow barely ended its longest continuous decline in 50 years, Micron fell by 16%, the US dollar reached a two-year high again, and US bonds, oil, and Bitcoin all dropped.
U.S. stock market's other Indexes turned down towards the end, Tesla rose by nearly 4% before closing down, NVIDIA reached a high of 4%, and Micron Technology had its steepest decline in five years. The yield on the 10-year U.S. Treasury bonds briefly increased by nearly 10 basis points approaching 4.60%, close to a seven-month high, while short-term bond yields fell, with the 2/10-year yield spread at its widest in two and a half years. The Bank of England held rates steady, but more officials supported a rate cut, leading to a decline in the British Pound. The Governor of the Bank of Japan suppressed interest rate hike expectations, causing the yen to fall towards 158, and the offshore renminbi briefly dropped below 7.32 yuan to its lowest in 15 months. Bitcoin fell by 5%, approaching $0.096 million. Spot Gold rose by 1.6% before narrowing back below $2,600, while the futures silver fell by 5%, and U.S. crude oil fell below $70.